BioXcel Therapeutics (BTAI) EPS (Weighted Average and Diluted) (2020 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly EPS (Weighted Average and Diluted) of -$0.54 in Q1 2026, down 183.08% quarter-over-quarter from $0.65 in Q4 2025, and up 64.0% on a YoY basis from -$0.33 in Q1 2025.
BioXcel Therapeutics (BTAI) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
BioXcel Therapeutics' EPS (Weighted Average and Diluted) history runs 7 years deep, the most recent figure standing at -$0.54 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 64.0% year-over-year to -$0.54; the TTM figure through Mar 2026 stood at -$4.52 (up 64.85% YoY), while the FY2025 annual figure was -$5.73, up 75.63% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.54 for Q1 2026 at BioXcel Therapeutics, down from $0.65 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.65 in Q4 2025 to a low of -$92.93 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$7.97 across 5 years, with a median of -$1.84 in 2023.
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) slumped 4641.33% in 2023, then surged 122.34% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.96 in 2022, then plunged by 4641.33% to -$92.93 in 2023, then jumped by 96.87% to -$2.91 in 2024, then jumped by 122.34% to $0.65 in 2025, then slumped by 183.08% to -$0.54 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.54 (Q1 2026), $0.65 (Q4 2025), and -$2.18 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.80 |
| 10 | BioXcel Therapeutics | 25.46 Mn | 25.46 Mn | -77,000.00 | -0.54 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.54 |
| Dec 31, 2025 | 0.65 |
| Sep 30, 2025 | -2.18 |
| Jun 30, 2025 | -2.45 |
| Mar 31, 2025 | -1.50 |
| Dec 31, 2024 | -2.91 |
| Sep 30, 2024 | -5.15 |
| Jun 30, 2024 | -3.30 |
| Mar 31, 2024 | -13.89 |
| Dec 31, 2023 | -92.93 |
| Sep 30, 2023 | -1.72 |
| Jun 30, 2023 | -1.83 |
| Mar 31, 2023 | -1.84 |
| Dec 31, 2022 | -1.96 |
| Sep 30, 2022 | -1.49 |
| Jun 30, 2022 | -1.35 |
| Mar 31, 2022 | -1.12 |
| Dec 31, 2021 | -0.92 |
| Sep 30, 2021 | -0.96 |
| Jun 30, 2021 | -1.11 |